Some studies indicate that low TIM-3 expression may be associated with favorable prognosis in NPM1-mutated AML, whereas higher TIM-3 expression is linked to significantly lower CR and survival rates at one-year follow-up (58). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.